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prognostic factors on treatment effect of MLC601 over 
2 years.  Methods: The CHIMES-E study evaluated the 2 years 
outcome of subjects aged  ≥ 18 years with acute ischemic 
stroke, National Institutes of Health Stroke Scale (NIHSS) 
score 6–14, pre-stroke modified Rankin Scale (mRS) score  ≤ 1 
included in a multicenter, randomized, double-blind, place-
bo-controlled trial of MLC601 for 3 months. Standard stroke 
care and rehabilitation were allowed during follow-up with 
mRS score being assessed in-person at month (M) 3 and by 
telephone at M1, M6, M12, M18 and M24.  Results: Data from 
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 Abstract 
 Background: The Chinese Medicine NeuroAiD Efficacy on 
Stroke recovery – Extension (CHIMES-E) study is among the 
few acute stroke trials with long-term outcome data. We 
aimed to evaluate the recovery pattern and the influence of 
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880 subjects were analyzed. There was no difference in base-
line characteristics between treatment groups. The propor-
tion of subjects with mRS score 0–1 increased over time in 
favor of MLC601 most notably from M3 to M6, thereafter re-
maining stable up to M24, while the proportion deteriorat-
ing to mRS score  ≥ 2 remained low at all time points. Older 
age (p < 0.01), female sex (p = 0.06), higher baseline NIHSS 
score (p < 0.01) and longer onset to treatment time (OTT; p 
< 0.01) were found to be predictors of poorer outcome at M3. 
Greater treatment effect, with more subjects improving on 
MLC601 than placebo, was seen among subjects with 2 or 
more prognostic factors (OR 1.65 at M3, 1.78 at M6, 1.90 at 
M12, 1.65 at M18, 1.39 at M24), especially in subjects with 
more severe stroke or longer OTT.  Conclusions: The sus-
tained benefits of MLC601 over 2 years were due to more 
subjects improving to functional independence at M6 and 
beyond compared to placebo. Selection of subjects with 
poorer prognosis, particularly those with more severe NIHSS 
score and longer OTT delay, as well as a long follow-up pe-
riod, may improve the power of future trials investigating 
the treatment effect of neuroprotective or neurorestorative 
therapies.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 
 Introduction 
 There are very few proven therapies in acute ischemic 
stroke that reduce disability and/or death apart from re-
vascularization strategies such as intravenous and endo-
vascular thrombolysis or thrombectomy, decompression 
surgery for ‘malignant’ cerebral infarction and organized 
in-patient stroke care  [1, 2] . Neuroprotection, aimed at 
restricting injury to the brain following an ischemic insult 
by preventing neuronal cell death in the salvageable pen-
umbra during the first hours of acute phase, has shown 
promising results in experimental studies  [3] , but have 
failed in many clinical trials due to a variety of factors in-
cluding patient selection and length of follow-up.
 More recently, therapeutic modalities to enhance the 
self-reparative processes in the brain after injury have 
emerged. MLC601 has shown neurorestorative and neu-
roprotective properties in cellular and animal models  [4, 
5] . As neurorestorative processes require time, it is ex-
pected that clinical benefits would gradually accrue and 
appear only after a longer period of observation following 
treatment initiation. This hypothesis has recently been 
confirmed in the Chinese Medicine NeuroAiD Efficacy 
on Stroke recovery – Extension (CHIMES-E) study which 
showed that a 3-month treatment course of MLC601 after 
an acute ischemic stroke increased the odds of achieving 
functional independence at 6 months and beyond  [6] . 
 Recovery from stroke, however, is dynamic and deterio-
ration may occur even after initial improvement  [7] . It is 
thus important to understand the pattern of long-term 
recovery of subjects with stroke in a neurorestorative tri-
al. In addition, we recently showed in the CHIMES study 
how predictors of functional outcome, such as age, sex, 
baseline National Institutes of Health Stroke Scale 
 (NIHSS) score, and treatment delay, affect the ability of 
demonstrating treatment effect of a therapy for stroke re-
covery at 3 months  [8, 9] .
 We hypothesized that the long-term benefit of MLC601 
was (1) due to improvement in functional outcomes per-
sisting over time among patients who received MLC601, 
and (2) greater in patients with poorer prognosis for re-
covery who have the potential to respond to treatment. 
Therefore, in this study, we aimed to evaluate the pat-
tern of recovery and the influence of prognostic factors 
on treatment effect of MLC601 over 2 years in the 
CHIMES-E study.
 Methods 
 Analyses were performed using data from the CHIMES and 
CHIMES-E studies. The CHIMES study is a randomized double-
blind placebo-controlled trial of subjects with ischemic stroke of 
intermediate severity allocated to either MLC601 or placebo for 
3 months as add-on treatment to standard therapies  [10] . Briefly, 
patients were included if they were 18 years or older, had an isch-
emic stroke in the preceding 72 h with NIHSS score of 6–14, brain 
imaging findings compatible with cerebral infarction and a pre-
stroke Modified Rankin Scale (mRS) score of  ≤ 1. Subjects were 
randomized to receive either MLC601 or matching placebo at a 
dose of 4 capsules 3 times daily for 3 months. Each 400 mg MLC601 
capsule contained extracts from 9 herbal components (Radix 
 astragali, Radix salviae mitorrhizae, Radix paeoniae rubra, 
 Rhizoma chuanxiong, Radix angelicae sinensis, Carthamus tincto-
rius, Prunus persica, Radix polygalae and Rhizoma acori tatari-
nowii) and 5 non-herbal components (Hirudo, Eupolyphaga 
seu steleophaga, Calculus bovis artifactus, Buthus martensii and 
 Cornu saigae tataricae).
 CHIMES-E is a planned extension study to evaluate the long-
term outcome of subjects included in CHIMES up to 2 years from 
stroke  [6] . Treatment allocation blinding was maintained through-
out the CHIMES-E study and all subjects received standard stroke 
care and appropriate rehabilitation as prescribed by the treating 
physician.
 Subjects were included in this analysis if they had the primary 
outcome, that is the mRS score, which was assessed in-person at 
month (M) 3 and by telephone at M1, M6, M12, M18 and M24. 
Logistic regression analyses were performed to identify the predic-
tors of mRS score  ≥ 2 and to assess the association between number 
of predictors and mRS. ORs and the corresponding 95% CIs ad-
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justed for age, sex, NIHSS score, pre-stroke mRS score and stroke 
onset to initiation of study treatment time (OTT) were used to es-
timate treatment effects overall and according to presence of pre-
dictors for poorer outcome. Percentages of subjects who improved 
to mRS score ≤1 or worsened to ≥2 at each time point were plotted. 
The numbers needed to treat (NNT) were calculated using the in-
verse of absolute differences (ADs) to estimate the clinical benefit 
of MLC601.
 Results 
 CHIMES-E included 880 subjects (MLC601, n = 446; 
placebo, n = 434) with mean age 61.8 ± 11.3 years, 36% 
women having mean baseline NIHSS score of 8.6 ± 2.5. 
Baseline characteristics of subjects were similar between 
the treatment groups as previously described  [6] .
 Overall, the odds of functional independence, defined 
as achieving mRS score  ≤ 1, increased over time in favor 
of MLC601 reaching statistical significance at M6, M12 
and M18 ( fig. 1 a). The proportion of subjects improving 
to mRS score 0–1 increased most at M3 and M6 and re-
mained stable over the next 18 months ( fig. 2 a). Overall, 
26% on MLC601 and 28% on placebo achieved mRS score 
 ≤ 1 at M1. This difference increased over subsequent 
months in favor of MLC601: 49 vs. 45% at M3, 55 vs. 46% 
at M6, 56 vs. 48% at M12, 56 vs. 48% at M18 and 56 vs. 
50% at M24 for MLC601 and placebo, respectively. On 
the other hand, the proportion of subjects deteriorating 
to mRS score  ≥ 2 remained low in both groups at all time 
points. At M24, 14 subjects on MLC601 and 19 subjects 
on placebo worsened to mRS score  ≥ 2. Both groups sim-
ilarly showed 1 recurrent stroke and 3 deaths, but no cog-
nitive decline.
 The predictive variables for mRS score  ≥ 2 at M3 were 
age >60 years (p < 0.01), baseline NIHSS score 10–14 
(p < 0.01), OTT >48 h (p < 0.01) and female sex (p = 
0.06). Increasing number of predictors was associated 
with worse mRS scores at M3 (cumulative OR 0.49, 95% 
CI 0.44–0.55), M6 (cumulative OR 0.51, 95% CI 0.45–
0.57), M12 (cumulative OR 0.51, 95% CI 0.45–0.57), 
M18 (cumulative OR 0.52, 95% CI 0.46–0.58) and 
M24 (cumulative OR 0.52, 95% CI 0.46–0.58). Greater 
treatment effects were seen among subjects with at least 
2 prognostic factors for poorer outcome for all time 
points showing ORs of 1.65 (95% CI 1.12–2.42) at M3, 
1.78 (95% CI 1.19–2.66) at M6, 1.90 (95% CI 1.27–2.85) 
at M12, 1.65 (95% CI 1.11–2.46) at M18 and 1.39 (95% 
CI 0.94–2.07) at M24 ( fig. 1 b). As expected, fewer sub-
jects achieved mRS 0–1 at M1, but the relative propor-
tion of subjects with better mRS scores over time was 
more evident in those treated with MLC601 than those 
treated with placebo ( fig. 2 b).
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 Fig. 1. Comparison of ORs of achieving 
mRS score  ≤ 1 at different time points in the 
overall CHIMES-E cohort ( a ) and in sub-
jects with at least 2 prognostic factors for 
poor outcome, that is, older age, female sex, 
baseline  NIHSS score  ≥ 10 and time to first 
dose  ≥ 48 h ( b ). 
a
Adjusted ORs
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 Treatment effects among older subjects were 1.33 
(95% CI 0.89–1.97) at M3, 1.69 (95% CI 1.12–2.55) at M6, 
1.60 (95% CI 1.06–2.41) at M12, 1.40 (95% CI 0.89–2.20) 
at M18, and 1.35 (95% CI 0.86–2.12) at M24. ORs for fe-
male subgroup were 1.84 (95% CI 1.15–2.94) at M3, 1.83 
(95% CI 1.12–2.99) at M6, 1.75 (95% CI 1.07–2.85) at 
M12, 1.57 (95% CI 0.96–2.56) at M18 and 1.35 (95% CI 
0.83–2.20) at M24. However, more severe NIHSS score 
and longer OTT as individual variables increased treat-
ment effect size and reduced NNT for all time points to 
almost the same magnitude as subjects with combina-
tions of any 2 or more prognostic factors for poor out-
come ( table 1 ).
 Discussion 
 Our analyses of long-term data from the CHIMES-E 
study provide important insights into the recovery pat-
terns of post-stroke subjects and the influence of progno-
Table 1.  Comparison of numbers needed to treat to gain an additional patient achieving mRS score ≤1 in overall study population and 
subgroups according to stroke severity and treatment delay
Overall NIHSS ≥10  OTT ≥48 h
n AD, % OR (95% CI) NNT n AD, % OR (95% CI) NNT n AD, % OR (95% CI) NNT
Month 3 982 3.8 1.28 (0.96–1.69) 27 325 9.5 1.63 (0.94–2.81) 11 482 9.3 1.57 (1.06–2.34) 11
Month 6 872 8.0 1.50 (1.11–2.02) 13 288 12.6 1.75 (1.00–3.07) 8 427 12.1 1.72 (1.13–2.62) 9
Month 12 871 7.1 1.42 (1.05–1.91) 14 288 16.7 2.15 (1.22–3.78) 6 427 11.6 1.67 (1.10–2.55) 9
Month 18 864 6.4 1.36 (1.01–1.84) 16 286 15.7 1.99 (1.15–3.46) 7 422 10.5 1.57 (1.03–2.40) 10
Month 24 856 5.3 1.31 (0.97–1.77) 19 280 13.4 1.76 (1.00–3.09) 8 415 8.9 1.48 (0.97–2.26) 12
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 Fig. 2. Proportions of subjects improving to mRS 0–1 or deteriorating to mRS score >2 over time in the overall CHIMES-E cohort ( a ) 
and among subjects with at least 2 prognostic factors for poor outcome, that is, older age, female sex, baseline NIHSS score  ≥ 10 and time 
to first dose  ≥ 48 h ( b ).  NA = MLC601; P = placebo.
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sis on treatment effect in a stroke recovery trial. We have 
previously reported the overall benefit of MLC601 on 
functional independence at 6 months and beyond  [6] . In 
this study, we demonstrate that the benefit was due to a 
larger proportion of subjects on MLC601 attaining func-
tional independence by 6 months, thereafter maintaining 
their functional independence for up to 2 years, with few-
er subjects deteriorating over time. In addition, we 
showed that subjects who have relatively poorer progno-
sis for recovery after a stroke are likely to obtain more 
benefit from treatment with MLC601.
 Acute stroke trials often follow subjects only for the 
first 3 months. This short period of observation may be 
insufficient to provide stroke patients with ample time to 
recover as brain reorganization and repair are complex 
continuing processes that may take many months and 
even years  [11] . Furthermore, it has been shown that 
transition from functional independence to dependency 
from 3 month to 1 year after a stroke is significant  [7] . At 
5 years, deterioration in functional and motor outcome 
may be observed with a return to the level measured at 
2 months after a stroke, particularly among subjects who 
are older and have suffered from a more severe stroke 
 [12] . These observations challenge the 3-month follow-
up often used as end point for evaluating stroke outcome 
 [13] .
 Our study included subjects with stroke of mild to 
moderate severity with a median baseline NIHSS score of 
8 (interquartile scores of 7 and 10)  [6] . As can be seen in 
the placebo group, more than a quarter of the subjects re-
covered to an independent functional state at 1 month and 
more than 45% were independent at 3 months after a 
stroke. As previously described, post-stroke patients re-
cover best during the first 3 months after a stroke  [14] . 
Patients with mild stroke recover fully by the third month. 
On the other hand, while steep recovery was seen among 
patients with moderate to severe strokes during the first 3 
months as well, this was not complete and the rate of re-
covery plateaus thereafter. Therefore, it is expected that 
treatment effects can be best demonstrated at 6 months 
and beyond in subjects who still have room to improve.
 Identification of such subjects for inclusion in a stroke 
recovery clinical trial is vital as such subjects will have 
the potential to benefit from investigational therapies. 
We have identified several factors that predict poorer 
outcomes at 3 months, namely older age, female sex, 
worse baseline stroke severity and longer delay between 
stroke onset and initiation of treatment  [6, 8–10, 15] . 
The same factors were reported in many in other previ-
ous studies  [16–22] and were also found to predict dete-
rioration at 1 and 5 years after a stroke  [7, 12, 22–24] . 
Many of our subjects did not experience deterioration at 
2 years; it was most likely due to exclusion of severe 
strokes in the trial. Nevertheless, we did see lower pro-
portions of subjects with poorer prognosis achieving 
functional independence (i.e., mRS score  ≤ 1) at all the 
time points and a trend for more long-term deteriora-
tion. Indeed, this led to the detection of larger treatment 
effects with relatively more subjects with poorer progno-
sis on MLC601 improving over time with less deteriora-
tion in the long run compared to placebo. This can rep-
resent as much as 138 additional patients achieving func-
tional independence at 12 months for every 1,000 patients 
treated.
 Among the prognostic factors we studied, we consid-
ered stroke severity (measured by NIHSS) and treatment 
window (indicated by OTT) as more important factors 
because they represent inherent disease- and treatment-
related variables to consider in designing clinical studies 
or in clinical practice with a strong influence on outcome 
after stroke. We recently showed that subjects with mod-
erately severe stroke and/or longer stroke OTT improve 
the power of detecting differences in recovery between 
treatment groups at 3 months  [9] . In this present analysis, 
NIHSS score and OTT individually improve the power 
even more after longer observations of up to 18 months, 
and NNT is low and stable over time, especially in sub-
jects with more severe strokes. The gradual decline in AD 
at 24 months is again seen and suggests that treatment 
longer than the 3-month regimen given in the study may 
be needed to maximize the brain repair processes in more 
subjects.
 There are some limitations in this study. As mentioned, 
our trial included only subjects with stroke of mild to 
moderate severity within 72 h. Whether the same findings 
can be seen in very severe cases or in longer time windows 
is unclear. The analyses were performed post-hoc. On the 
other hand, the strength of our study is that our trial is one 
of the few stroke trials providing long-term data collected 
with full blinding maintained throughout.
 In conclusion, the sustained benefits seen with MLC601 
were due to more post-stroke subjects improving to func-
tional independence at 6 months and beyond with very 
few subjects deteriorating over time compared to place-
bo. Prognostic factors for poorer outcome, particularly 
baseline stroke severity and treatment delay, improve the 
power of demonstrating the treatment effect of MLC601. 
Furthermore, our results indicate that longer observa-
tions and treatment duration can maximize the recovery 
potential of subjects included in post-acute stroke trials. 
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Future stroke trials should consider long-term follow-up 
of selected subjects who have relatively poorer prognosis 
and have the potential for recovery.
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